avatrombopag Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Avatrombopag was discovered by Yamanouchi Pharmaceutical, developed by AkaRx which late became acquired by Dova Pharmaceuticals. In 2018 avatrombopag was approved by the FDA for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.   NCATS

Chemistry

  • SMILES: OC(=O)C1CCN(CC1)c2ncc(cc2Cl)C(=O)Nc3nc(c4cc(Cl)cs4)c(s3)N5CCN(CC5)C6CCCCC6
  • InChIKey: OFZJKCQENFPZBH-UHFFFAOYSA-N
  • Mol. Mass: 649.67
  • ALogP: 6.58
  • ChEMBL Molecules:
    avatrombopag  
    avatrombopag maleate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$201.2460 - $299.5560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid | akr501 | akr 501 | akr-501 | avatrombopag | avatrombopag maleate | e5501 | e5501 compound | e5501 maleate | ym477 | ym 477 | ym-477

Organizations (23)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Thrombocytopenia (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Acute-On-Chronic Liver Failure (Phase 4)

Anemia, Aplastic (Phase 2/Phase 3)

Anemia, Hemolytic, Autoimmune (Phase 4)

Autoantibodies (Phase 4)

Blood Platelet Disorders (Phase 2)

Connective Tissue Diseases (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Healthy Volunteers (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)

Hemorrhage (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 2)

Liver Failure (Phase 4)

Lymphoma (Phase 2)

Neoplasms (Phase 2)

Pharmacokinetics (Phase 2/Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Thrombocytopenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue